NDC 53329-601-28 - Medline
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 53329-601
- Requested NDC
- 53329-601-28
- Package NDCs from labels
- 53329-601-28, 53329-601-09
- Manufacturer
- Medline Industries, LP
- Effective date
- 2026-08-28
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Medline - Medline Industries, LP | Medline Industries, LP | 2026-08-28 | HUMAN OTC DRUG LABEL |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| good sense headache relief | ACETAMINOPHEN, ASPIRIN, CAFFEINE | L. Perrigo Company | 4cae0580-7ee3-4f38-8d13-79c7d7615f8f | 2025-08-12 | Warnings | R16CO5Y76E |
| Aspirin | ASPIRIN | PROSTAT FIRST AID | 3bdb9d89-9000-69f9-e063-6294a90a0c97 | 2025-08-08 | Warnings | R16CO5Y76E |
| Aspirin Low Dose | ASPIRIN | A-S Medication Solutions | 8575ef9d-2eae-412a-a252-82b03f4d5275 | 2025-08-08 | Warnings | R16CO5Y76E |
| Aspirin | ASPIRIN | A-S Medication Solutions | 7a91b1df-8d6d-4205-9822-bc4d800555f7 | 2025-08-08 | Warnings | R16CO5Y76E |
| Aspirin | ASPIRIN | A-S Medication Solutions | 44b8c203-37c5-425e-9110-f7eb614f9c2d | 2025-08-08 | Warnings | R16CO5Y76E |
| Low Dose Aspirin | ASPIRIN | CHAIN DRUG MARKETING ASSOCIATION INC | c46688ec-e976-4f76-9265-645f59970ff5 | 2025-08-06 | Warnings | R16CO5Y76E |
| Headache Relief Extra Strength | ACETAMINOPHEN, ASPIRIN, CAFFEINE | P & L Development, LLC | c54ad829-f2e8-4367-b439-af20b0ef8ad2 | 2025-08-06 | Warnings | R16CO5Y76E |
| Exaprin Plus | ASPIRIN, ACETAMINOPHEN, CAFFEINE | HART Health | 8a9ca680-e6cf-4ee4-8a5f-bd6d7470b848 | 2025-08-04 | Warnings | R16CO5Y76E |
| Aspirin | ASPIRIN | Proficient Rx LP | 2ef0757a-fe5f-47de-906a-a4d47a0d0534 | 2025-08-01 | Warnings | R16CO5Y76E |
| EXTRA STRENGTH HEADACHE RELIEF | ACETAMINOPHEN ASPIRIN CAFFEINE | WAL-MART STORES INC | d97073cd-b5d7-8c09-e053-2a95a90a8938 | 2025-07-16 | Warnings | R16CO5Y76E |
| EXTRA STRENGTH PAIN RELIEF | ACETAMINOPHEN, ASPIRIN, CAFFEINE | BETTER LIVING BRANDS, LLC | eb6026d5-d88a-f6b3-e053-2a95a90a5b20 | 2025-07-15 | Warnings | R16CO5Y76E |
| EXTRA PAIN RELIEF | ACETAMINOPHEN, ASPIRIN AND CAFFEINE | TIME CAP LABS | 59482917-f80b-4bed-9218-068b35366eb3 | 2025-07-11 | Warnings | R16CO5Y76E |
| HEADACHE RELIEF | ACETAMINOPHEN, ASPIRIN AND CAFFEINE | Kroger Company | bbed29a1-3c52-3531-e053-2995a90a686c | 2025-07-10 | Warnings | R16CO5Y76E |
| Adult Low Dose Aspirin | ASPIRIN | Advanced Rx LLC | ad0d6a5c-eee9-406c-8d7f-1df9b45f5340 | 2025-07-02 | Warnings | R16CO5Y76E |
| EXTRA STRENGHT HEADACHE RELIEF | ACETAMINOPHEN, ASPIRIN, CAFFEINE | Lil' Drug Store Products, Inc. | ec04eb5d-96c0-ddb4-e053-2a95a90a4a92 | 2025-07-02 | Warnings | R16CO5Y76E |
| Acetaminophen, Aspirin, and Caffeine | ACETAMINOPHEN, ASPIRIN, AND CAFFEINE | Bi-Mart | 40cd1a7a-e941-4503-8fe4-e939bd0d9d72 | 2025-07-02 | Warnings | R16CO5Y76E |
| Aspirin Regular Strength | ASPIRIN | United Natural Foods, Inc. dba UNFI | 979973c1-661a-4384-8b92-fd901ebde558 | 2025-07-01 | Warnings | R16CO5Y76E |
| EXCEDRIN MIGRAINE | ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE | Haleon US Holdings LLC | 7ed841fb-a61c-4868-b4e5-4f2311a5e79c | 2025-06-25 | Warnings | R16CO5Y76E |
| Regular Strength Enteric coated aspirin | ASPIRIN | ATLANTIC BIOLOGICALS CORP. | e1c8d0ed-da1d-4b1a-9a85-7b8532775f87 | 2025-06-24 | Warnings | R16CO5Y76E |
| Aspirin Low Dose | ASPIRIN | ATLANTIC BIOLOGICALS CORP. | 024c5054-959f-4ea5-a71f-c0e16cc4b90c | 2025-06-24 | Warnings | R16CO5Y76E |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.